imo-8400
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01899729)
Timeline
Indications
Mechanism of action
- Toll-like receptor 9ANTAGONIST
TLR9 antagonist
- TLR7 and TLR8ANTAGONIST
TLR7 and TLR8 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- imo-8400
- imo-8400
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02612857 | Phase 2 | Nov 1, 2015 | Aceragen, Inc/ |
| NCT02363439 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | Aceragen, Inc/ |
| NCT02252146 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Aceragen, Inc/ |
| NCT02092909 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Aceragen, Inc/ |
| NCT01899729 | Phase 2 | May 1, 2013 | Aceragen, Inc/, Leiden University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aceragen, Inc/ | For profit | 5 | 5 | 1 | 2013 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1